S. Buell Jennifer's Insider Trades & SAST Disclosures
S. Buell Jennifer's most recent trade in Agenus Inc was a trade of 581 Common Stock done at an average price of $3.1 . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern S. Buell Jennifer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 3.11 per share. | 02 May 2025 | 581 | 19,738 (0%) | 0% | 3.1 | 1,807 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 2.08 per share. | 18 Apr 2025 | 869 | 19,157 (0%) | 0% | 2.1 | 1,808 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 1.56 per share. | 04 Apr 2025 | 1,159 | 18,288 (0%) | 0% | 1.6 | 1,808 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 1.61 per share. | 21 Mar 2025 | 1,123 | 17,129 (0%) | 0% | 1.6 | 1,808 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 2.35 per share. | 07 Mar 2025 | 409 | 15,646 (0%) | 0% | 2.3 | 961 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 3.32 per share. | 21 Feb 2025 | 626 | 15,318 (0%) | 0% | 3.3 | 2,078 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 3.32 per share. | 21 Feb 2025 | 545 | 15,237 (0%) | 0% | 3.3 | 1,809 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 07 Feb 2025 | 516 | 14,692 (0%) | 0% | 3.5 | 1,806 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Grant, award, or other acquisition of securities at price $ 3.57 per share. | 24 Jan 2025 | 776 | 14,446 (0%) | 0% | 3.6 | 2,770 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.57 per share. | 24 Jan 2025 | 270 | 14,176 (0%) | 0% | 3.6 | 964 | Common Stock |
| Agenus Inc | Jennifer S. Buell | Director, Chairman Executive Council | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2024 | 300,000 | 300,000 | - | - | Stock Option | |
| MiNK Therapeutics Inc | S. Buell Jennifer | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 660,919 | 660,919 | - | - | Stock Option | |
| MiNK Therapeutics Inc | Buell S. Jennifer | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 500,000 | 500,000 | - | - | Stock Option | |
| MiNK Therapeutics Inc | Jennifer S. Buell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 500,000 | 500,000 | - | - | Stock Option | |
| MiNK Therapeutics Inc | Jennifer S. Buell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.32 per share. | 09 Jan 2023 | 171,990 | 380,715 | - | 2.3 | 399,017 | Common Stock |
| MiNK Therapeutics Inc | Jennifer S. Buell | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 679,800 | 679,800 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges